Key Highlights
- Second-quarter revenue was $652.5 million versus about $599.8 million expected.
- 2026 revenue guidance was raised to $2.6–$2.7 billion.
- Adjusted EBITDA guidance was tightened to $120–$135 million.
- Third-quarter results will be released on November 5, 2026.
Evolent Health, Inc. (NYSE:EVH) is in focus as it heads toward its third-quarter report, which the company announced on October 9, 2026 it will release on November 5. The company has a market capitalisation of about $480 million. Management raised its 2026 revenue guidance in August, and several analysts have lifted or reiterated targets.
Latest Company Context
Evolent provides specialty care management in oncology, cardiology and musculoskeletal care for health plans, supported by its Identifi technology platform, and employs about 4,200 people. Second-quarter 2026 results, reported August 6, showed revenue of $652.5 million, above a consensus of about $599.8 million. Management raised 2026 revenue guidance to $2.6 billion to $2.7 billion from $2.4 billion to $2.6 billion and tightened adjusted EBITDA guidance to $120 million to $135 million. The call transcript indicated management expects revenue growth above 25% in 2027 despite Medicaid and exchange headwinds. Trailing revenue is $2.10 billion, but the company recorded a net loss of about $511 million over that period. In September it selected TransPerfect for telephonic interpretation services.
Key Business Drivers
The first is specialty-care volumes and the performance of value-based contracts, where cost trends can quickly alter margins. The second is exposure to Medicaid and ACA exchange populations, which management itself noted as headwinds. The third is profitability: the adjusted EBITDA range is solid relative to revenue, but the reported net loss shows that non-cash and other items remain significant. The fourth is the balance sheet and capital allocation, including capitalised software spending guided at $25 million to $30 million. Analyst views are mixed, with Truist moving to Hold earlier in the summer.
What Investors Should Watch
The next catalyst is the Q3 release on November 5, 2026. Investors may watch whether revenue and adjusted EBITDA track the raised guidance, how new contract wins ramp, and whether management provides more detail on 2027. Analyst consensus is Buy from 14 analysts with an average target of about $5.75, with JPMorgan and TD Cowen at $6 and Canaccord cutting to $6 from $7 after Q2. Regulatory changes in Medicaid and exchange markets, and any developments in health-plan partner contracts, could also matter.
Higher Guidance and Analyst Support Beside a Continuing Net Loss
Evolent's guidance increase and analyst support contrast with a continuing reported net loss. Whether growth converts into earnings and cash will be visible in the November 5 report.






Please wait processing your request...